All In Biotech

Drug Trial Radar · NCT00519675

Alitretinoin in the Treatment of Chronic Hand Eczema

Open Label Treatment of Patients With Chronic Hand Dermatitis Who Have Participated in a Previous Clinical Trial Involving Oral Alitretinoin

Last checked: Nov 20, 2026Latest source record: May 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Planned (sponsor's estimate)

Start

May 2007

Primary completion

Not stated

Sponsor

Lead sponsor
Basilea PharmaceuticaIndustry
Sponsor type
Industry
First posted
Aug 23, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to investigate the safety and efficacy of alitretinoin in chronic hand eczema that is refractory to topical corticosteroids.

Conditions

  • Eczema

Interventions

  • alitretinoinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety assessments

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Paris, France

  • Site not named

    Saint-Etienne, France

  • Site not named

    Berlin, Germany

  • Site not named

    Dresden, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.